1. Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment
2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®
You may not be if
1\) Patients with conditions in which any study drug is contraindicated per the respective approved label.
Clareo Health | Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
